We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Apollon Formularies plc (APOL) ORD NPV

Sell:0.07p Buy:0.12p Change: No change
Market closed |  Prices as at close on 27 March 2024 | Switch to live prices |
Sell:0.07p
Buy:0.12p
Change: No change
Market closed |  Prices as at close on 27 March 2024 | Switch to live prices |
Sell:0.07p
Buy:0.12p
Change: No change
Market closed |  Prices as at close on 27 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Apollon Formularies plc is a United Kingdom-based medical cannabis pharmaceutical company. The Company is engaged in specializing in research and treatment of patients with cancer and chronic pain. The Company has hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products. Its products with trademarks include APOLLON-Full Extract Cannabis Oil (FECO) Vape, APOLLON FECO Oral Tincture-30ml Bottle, and APOLLON FECO Prescribed Capsules. It also includes Apollon NAUSEA Apollon PAIN, Apollon SLEEP, Apollon ANTI-INFLAMMATORY, Apollon SEIZURES, Apollon APPETITE, and Apollon CANCER. It offers services, including cultivation, processing and extraction, international cancer institute, retail product sales, Apollon Negril facility, research and development, and bespoke treatments and products. The Company’s wholly owned subsidiary is Apollon Formularies Ltd.

Contact details

Address:
Ste 3b, 38 Jermyn Street
LONDON
SW1Y 6DN
United Kingdom
Telephone:
+44 (020) 74400640
Website:
https://www.afriagglobal.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

EPIC:
APOL
ISIN:
IM00BJ0LRD77
Market cap:
£749,730
Shares in issue:
771.19 million
Sector:
Pharmaceuticals
Exchange:
-
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • David Lenigas
    Executive Chairman of the Board
  • Stene Jacobs
    Chief Operating Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.